CTOs on the Move

Day One Biopharmaceuticals

www.dayonebio.com

 
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.dayonebio.com
  • 395 Oyster Point Blvd Suite 217
    South San Francisco, CA USA 94080
  • Phone: 650.770.9034

Executives

Name Title Contact Details

Funding

Day One Biopharmaceuticals raised $60M on 05/21/2020
Day One Biopharmaceuticals raised $130M on 02/10/2021

Similar Companies

CervoMed

CervoMed is a public, Boston, MA-based company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases. CervoMed was launched in 2014 as EIP Pharma, Inc, by R&D executives from the pharmaceutical and biotech industry. In August, 2023 EIP Pharma merged with Diffusion Pharmaceuticals, retaining EIPs development pipeline, but changing their name to CervoMed (CRVO). For more information about the company and updates, please visit www.cervomed.com/ or follow us on Twitter at @Cervo_Med.

Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Progenics

Progenics is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marlon Ramos at Frange Blue-Hairstylist

Marlon Ramos at Frange Blue-Hairstylist is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cerulean

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.